Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results

View Press | Corbis News | Getty ImagesPfizer on Tuesday hiked its full-year adjusted fit guidance on its cost cuts and strong performance this year.The company also reported second-quarter results that topped Wall Street's estimates for the period, as revenue from its Covid ducts and some other drugs jumped.s of Pfizer rose more than 2% in premarket trading on Tuesday.Pfizer now expects full-year adjusted fit to come in between $2.90 to $3.10, up from a previous guidance of $2.80 to $3 per

The company maintained its 2025 revenue forecast of $61 billion to $64 billion."We raised our full-year 2025 Adjusted diluted EPS guidance, demonstrating confidence in our ability to execute against our strategic priorities and der strong results for holders," Pfizer CFO David Denton said in a release

That charge will be recorded in the third quarter, Pfizer said

The results also come as Pfizer and other drugmakers grapple with President Donald Trump's calls to lower drug prices in the U.S. and brace for his planned tariffs on pharmaceuticals imported into the country.Pfizer's outlook accounts for Trump's currently imposed tariffs on China, Canada and Mexico, as well as potential drug price changes this year based on a letter from the president last week calling on Pfizer to take steps to lower drug prices by Sept. 29

The letter came after Trump in May signed an executive order reviving a controversial plan, the "most favored nation" policy, that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad.Pfizer's release on Tuesday did not vide specific costs for those factors

In April, Pfizer executives said the company's 2025 guidance at the time included $150 million in expected costs from Trump's existing tariffs, but not sector-specific levies.Here's what the company reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per : 78 cents adjusted vs. 58 cents expectedRevenue: $14.65 billion vs. $13.56 billion expectedFor the second quarter, Pfizer booked net income of $2.91 billion, or 51 cents per

Excluding certain items, including restructuring charges and costs associated with intangible assets, the company posted earnings per of 78 cents for the quarter.Pfizer reported revenue of $14.65 billion for the second quarter, up 10% from the same period a year ago.The results come after Pfizer in April expanded its cost-cutting efforts, which aim to help the pharmaceutical giant recover from the rapid decline of its Covid and stock price over the past few years

With the added cuts announced in April, Pfizer now expects to der around $7.7 billion in savings by the end of 2027 from two separate cost-cutting grams.Strength from Covid ducts, other drugsThe company said the increase in sales was primarily driven by higher revenues for several ducts, including Pfizer's Vyndaqel drugs, which are used to treat a certain type of cardiomyopathy, a disease of the heart muscle

It also includes Pfizer's Covid ducts

Analysts expected the shot to rake in $205.3 million in sales for the quarter, according to StreetAccount estimates.Pfizer's antiviral Covid pill Paxlovid posted $427 million in sales for the second quarter

That sales increase was offset by lower Covid infections across the U.S. and certain international , and lower international government purchases of Paxlovid

Analysts expected the shot to rake in $259.1 million in sales for the period, StreetAccount estimates said.Pfizer's bladder cancer drug Padcev and blood thinner Eliquis, which it s with Bristol Myers Squibb, also contributed to revenue growth

Both topped analysts' estimates for the period

The company's revenue growth was offset by lower sales from its breast cancer drug Ibrance

The drug had a lower U.S. net price largely due to the impact of higher manufacturer discounts from visions of the Inflation Reduction Act that redesign Medicare Part D benefits, as well as generic competition and the timing of shipments in certain international .